Ayodeji Adegunsoye1, Justin M Oldham2, Shashi K Bellam3, Steven Montner4, Matthew M Churpek1,5, Imre Noth6, Rekha Vij1, Mary E Strek1, Jonathan H Chung4. 1. 1 Section of Pulmonary and Critical Care, Department of Medicine. 2. 2 Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California at Davis, Davis, California. 3. 3 Division of Pulmonary and Critical Care, Department of Medicine, NorthShore University HealthSystem, Evanston, Illinois; and. 4. 4 Department of Radiology, and. 5. 5 Department of Public Health Sciences, The University of Chicago, Chicago, Illinois. 6. 6 Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.
Abstract
Rationale: Honeycombing on chest computed tomography (CT) has been described in diverse forms of interstitial lung disease (ILD); however, its prevalence and association with mortality across the spectrum of ILD remains unclear. Objective: To determine the prevalence and prognostic value of CT honeycombing and characterize associated mortality patterns across diverse ILD subtypes in a multicenter cohort. Methods: This was an observational cohort study of adult participants with multidisciplinary or adjudicated ILD diagnosis and documentation of chest CT imaging at index diagnosis across five U.S. hospitals (one tertiary and four nontertiary medical centers). Participants were stratified based on presence or absence of CT honeycombing. Vital status was determined from review of medical records and social security death index. Transplant-free survival was analyzed using univariate and multivariable Cox regression. Results: The sample comprised 1,330 participants (mean age, 66.8 yr; 50% men) with 4,831 person-years of follow-up. The prevalences of CT honeycombing were 42.0%, 41.9%, 37.6%, and 28.6% in chronic hypersensitivity pneumonitis, connective tissue disease-related ILD (CTD-ILD), idiopathic pulmonary fibrosis (IPF), and unclassifiable/other ILDs, respectively. Among those with CT honeycombing, cumulative mortality hazards were similar across ILD subtypes, except for CTD-ILD, which had a lower mortality hazard. Overall, the mean survival time was shorter among those with CT honeycombing (107 mo; 95% confidence interval [CI], 92-122 mo) than those without CT honeycombing (161 mo; 95% CI, 147-174 mo). CT honeycombing was associated with an increased mortality rate (hazard ratio, 1.72; 95% CI, 1.38-2.14) even after adjustment for center, sex, age, forced vital capacity, diffusing capacity, ILD subtype, and use of immunosuppressive therapy (hazard ratio, 1.62; 95% CI, 1.29-2.02). CT honeycombing was associated with an increased mortality rate within non-IPF ILD subgroups (chronic hypersensitivity pneumonitis, CTD-ILD, and unclassifiable/other ILD). In IPF, however, mortality rates were similar between those with and without CT honeycombing. Conclusions: CT honeycombing is prevalent in diverse forms of ILD and uniquely identifies a progressive fibrotic ILD phenotype with a high mortality rate similar to IPF. CT honeycombing did not confer additional risk in IPF, which is already known to be a progressive fibrotic ILD phenotype regardless of the presence of CT honeycombing.
Rationale: Honeycombing on chest computed tomography (CT) has been described in diverse forms of interstitial lung disease (ILD); however, its prevalence and association with mortality across the spectrum of ILD remains unclear. Objective: To determine the prevalence and prognostic value of CT honeycombing and characterize associated mortality patterns across diverse ILD subtypes in a multicenter cohort. Methods: This was an observational cohort study of adult participants with multidisciplinary or adjudicated ILD diagnosis and documentation of chest CT imaging at index diagnosis across five U.S. hospitals (one tertiary and four nontertiary medical centers). Participants were stratified based on presence or absence of CT honeycombing. Vital status was determined from review of medical records and social security death index. Transplant-free survival was analyzed using univariate and multivariable Cox regression. Results: The sample comprised 1,330 participants (mean age, 66.8 yr; 50% men) with 4,831 person-years of follow-up. The prevalences of CT honeycombing were 42.0%, 41.9%, 37.6%, and 28.6% in chronic hypersensitivity pneumonitis, connective tissue disease-related ILD (CTD-ILD), idiopathic pulmonary fibrosis (IPF), and unclassifiable/other ILDs, respectively. Among those with CT honeycombing, cumulative mortality hazards were similar across ILD subtypes, except for CTD-ILD, which had a lower mortality hazard. Overall, the mean survival time was shorter among those with CT honeycombing (107 mo; 95% confidence interval [CI], 92-122 mo) than those without CT honeycombing (161 mo; 95% CI, 147-174 mo). CT honeycombing was associated with an increased mortality rate (hazard ratio, 1.72; 95% CI, 1.38-2.14) even after adjustment for center, sex, age, forced vital capacity, diffusing capacity, ILD subtype, and use of immunosuppressive therapy (hazard ratio, 1.62; 95% CI, 1.29-2.02). CT honeycombing was associated with an increased mortality rate within non-IPF ILD subgroups (chronic hypersensitivity pneumonitis, CTD-ILD, and unclassifiable/other ILD). In IPF, however, mortality rates were similar between those with and without CT honeycombing. Conclusions: CT honeycombing is prevalent in diverse forms of ILD and uniquely identifies a progressive fibrotic ILD phenotype with a high mortality rate similar to IPF. CT honeycombing did not confer additional risk in IPF, which is already known to be a progressive fibrotic ILD phenotype regardless of the presence of CT honeycombing.
Authors: Ayodeji Adegunsoye; Justin M Oldham; Catherine Bonham; Cara Hrusch; Paul Nolan; Wesley Klejch; Shashi Bellam; Uday Mehta; Kiran Thakrar; Janelle Vu Pugashetti; Aliya N Husain; Steven M Montner; Christopher M Straus; Rekha Vij; Anne I Sperling; Imre Noth; Mary E Strek; Jonathan H Chung Journal: Am J Respir Crit Care Med Date: 2019-03-15 Impact factor: 21.405
Authors: Zulma X Yunt; Jonathan H Chung; Stephen Hobbs; Evans R Fernandez-Perez; Amy L Olson; Tristan J Huie; Rebecca C Keith; William J Janssen; Barbara L Goldstein; David A Lynch; Kevin K Brown; Jeffrey J Swigris; Joshua J Solomon Journal: Respir Med Date: 2017-03-30 Impact factor: 3.415
Authors: Jonathan H Chung; Justin M Oldham; Steven M Montner; Rekha Vij; Ayodeji Adegunsoye; Aliya N Husain; Imre Noth; David A Lynch; Mary E Strek Journal: AJR Am J Roentgenol Date: 2018-03-16 Impact factor: 3.959
Authors: Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek Journal: Eur Respir J Date: 2018-06-14 Impact factor: 16.671
Authors: Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg Journal: BMJ Open Respir Res Date: 2017-09-17
Authors: Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: David Pritchard; Ayodeji Adegunsoye; Elyse Lafond; Janelle Vu Pugashetti; Ryan DiGeronimo; Noelle Boctor; Nandini Sarma; Isabella Pan; Mary Strek; Michael Kadoch; Jonathan H Chung; Justin M Oldham Journal: Respir Res Date: 2019-11-12
Authors: Paolo Spagnolo; Oliver Distler; Christopher J Ryerson; Argyris Tzouvelekis; Joyce S Lee; Francesco Bonella; Demosthenes Bouros; Anna-Maria Hoffmann-Vold; Bruno Crestani; Eric L Matteson Journal: Ann Rheum Dis Date: 2020-10-09 Impact factor: 19.103
Authors: David Lang; Florentine Moazedi-Fürst; Judith Sautner; Helmut Prosch; Sabin Handzhiev; Klaus Hackner; Ivan Tancevski; Holger Flick; Hubert Koller; Hans Peter Kiener; Christian Prior; Bernd Lamprecht Journal: Wien Klin Wochenschr Date: 2021-05 Impact factor: 1.704
Authors: Zouina Sarfraz; Azza Sarfraz; Alanna Barrios; Radhika Garimella; Asimina Dominari; Manish Kc; Krunal Pandav; Juan C Pantoja; Varadha Retnakumar; Ivan Cherrez-Ojeda Journal: J Prim Care Community Health Date: 2021 Jan-Dec
Authors: Kevin K Brown; Fernando J Martinez; Simon L F Walsh; Victor J Thannickal; Antje Prasse; Rozsa Schlenker-Herceg; Rainer-Georg Goeldner; Emmanuelle Clerisme-Beaty; Kay Tetzlaff; Vincent Cottin; Athol U Wells Journal: Eur Respir J Date: 2020-06-25 Impact factor: 16.671
Authors: Regina Celia Carlos Tibana; Maria Raquel Soares; Karin Mueller Storrer; Gustavo de Souza Portes Meirelles; Katia Hidemi Nishiyama; Israel Missrie; Ester Nei Aparecida Martins Coletta; Rimarcs Gomes Ferreira; Carlos Alberto de Castro Pereira Journal: BMC Pulm Med Date: 2020-11-16 Impact factor: 3.317